PBAC blocks access to new myeloma drugs: Prof Andrew Spencer

Australian blood cancer patients are being denied access to life-extending drugs and treatments because of long delays and excessive regulation by the Pharmaceutical Benefits Advisory Committee (PBAC), a parliamentary inquiry has been told. Leading haematologist Professor Andrew Spencer said the registry of myeloma cases established some eight years ago showed “very poor” outcomes for myeloma ...

Already a member?

Login to keep reading.

© 2021 the limbic